Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 5/20 | 0.51 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | TRPC6 | Q9Y210 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21473565 | 0.89 | KDM4E (0.58) | HTR4EHMT2PDPK1EGFRKDM4E | |
| SCHEMBL30017160 | 0.89 | KDM4E (0.58) | HTR4EHMT2PDPK1EGFRKDM4E | |
| SCHEMBL1613999 | 0.86 | HTR4 (0.47) | HTR4EHMT2PDPK1KDM4EACHE | |
| SCHEMBL8306125 | 0.86 | EHMT2 (0.53) | HTR4EHMT2PDPK1EGFRKDR | |
| SCHEMBL4430393 | 0.82 | KDM4E (0.46) | EGFRKDM4E | |
| SCHEMBL17375537 | 0.79 | HTR4 (0.47) | HTR4EHMT2EGFRKDM4EKDR | |
| SCHEMBL4425396 | 0.78 | TSHR (0.57) | KDM4E | |
| SCHEMBL5023831 | 0.78 | ABL1 (0.52) | HTR4EHMT2PDPK1EGFRKDR | |
| SCHEMBL8305831 | 0.78 | EHMT2 (0.44) | HTR4EHMT2PDPK1EGFRKDR | |
| SCHEMBL6406771 | 0.77 | HTR4 (0.50) | HTR4KDM4EACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498335-B2 | Method of producing an antiangiogenic or vascular permeability reducing effect | ASTRAZENECA AB (CH) | 2009-03-03 | — | — | US | disclosed |
| EP-1296973-B1 | GUANIDINE DERIVATIVES OF QUINAZOLINE FOR USE IN THE TREATMENT OF AUTOIMMUNE DISEASES | ASTRAZENECA AB (SE) | 2008-11-05 | — | — | EP | disclosed |
| EP-1381599-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2008-09-24 | — | — | EP | disclosed |
| EP-1218353-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA UK LTD (GB) | 2007-10-17 | — | — | EP | disclosed |
| EP-1272185-B1 | USE OF QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS | ASTRAZENECA AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| US-20040138240-A1 | Quinazoline derivatives | ASTRAZENECA AB (SE) | 2004-07-15 | — | — | US | disclosed |
| US-20030225111-A1 | Therapy | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138240-A1 | Quinazoline derivatives | NQO2, WEE1, CMA1 | HTR4 3916/4885EHMT2 1923/4885PDPK1 2671/4885 |
| US-20030225111-A1 | Therapy | VEGFA, AQP1, FLT1 | HTR4 1654/4885EHMT2 3260/4885PDPK1 4085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.